KIBRA (kidney-and brain-expressed protein) is a novel regulator of the Hippo pathway, which controls tissue growth and tumorigenesis by regulating both cell proliferation and apoptosis. In mammals, KIBRA is associated with memory performance. The physiological function and regulation of KIBRA in nonneuronal cells remain largely unclear. We reported recently that KIBRA is phosphorylated by the mitotic kinases Aurora-A and -B. In the present study, we have expanded our analysis of KIBRA's role in cell-cycle progression. We show that KIBRA is also phosphorylated by CDK1 (cyclin-dependent kinase 1) in response to spindle damage stress. We have identified KIBRA Ser 542 and Ser 931 as main phosphorylation sites for CDK1 both in vitro and in vivo. Moreover, we found that the CDC (cell division cycle) 14A/B phosphatases associate with KIBRA, and CDK1-nonphosphorylatable KIBRA has greatly reduced interaction with CDC14B. CDC14A/B dephosphorylate CDK1-phosphorylated KIBRA in vitro and in cells. By using inducible-expression cell lines, we show further that phospho-regulation of KIBRA by CDK1 and CDC14 is involved in mitotic exit under spindle stress. Our results reveal a new mechanism through which KIBRA regulates cell-cycle progression.
INTRODUCTION
KIBRA, a WW domain-containing protein, is highly expressed in kidney and brain [1] . KIBRA was identified as a memory performance-associated protein [2] [3] [4] [5] [6] . This function is linked to a C>T single nucleotide polymorphism in the ninth intron of the KIBRA gene [2] . A recent report using a knockout mouse model confirmed further that KIBRA plays a role in learning and memory [7] . Besides the function in neurons, KIBRA is also involved in diverse processes in non-neuronal cells. For example, KIBRA has been shown to interact with the polarity protein PATJ [PALS1 (protein associated with Lin7 1)-associated tight junction] and synaptopodin, and it regulates podocyte migration [8] . Furthermore, KIBRA mediates the aPKC (atypical protein kinase C)-exocyst interaction and is also required for NRK (normal rat kidney) cell migration [9] . It was demonstrated recently that KIBRA regulates epithelial cell polarity by suppressing apical exocytosis through inhibition of aPKC activity in the PAR (partitioning-defective) 3-aPKC-PAR6 tight junction complex [10] . KIBRA also modulates the collageninduced ERK (extracellular-signal-regulated kinase) signalling via interactions with discoidin domain receptor tyrosine kinase 1 [11] . Genetic studies in Drosophila have identified KIBRA as a potential tumour suppressor acting through the Hippo signalling pathway [12] [13] [14] , which is a central player in controlling organ size, tumorigenesis and cell contact inhibition by inhibiting cell proliferation and promoting apoptosis [15] [16] [17] . Interestingly, KIBRA expression is frequently down-regulated by promoter methylation in B-cell acute lymphocytic leukaemia [18] and chronic lymphocytic leukaemia [19] ; however, the molecular function of methylation/demethylation at the KIBRA locus in leukaemia has not been determined. We demonstrated recently that KIBRA is also a negative regulator of the Hippo pathway in mammalian cells [20] .
Mitosis is a critical step to ensure the genome integrity during cell-cycle progression. Thus aberration of mitosis is often seen in human malignancy. Interestingly, several components of the Hippo pathway have been shown to be important regulators of mitosis [21] [22] [23] , implicating a new mechanism through which the Hippo pathway exerts its tumour-suppressive function in cancer. Microtubules play pivotal roles in mitosis and cell division and are targets of anti-mitotic chemotherapeutics [24, 25] . Spindle poisons, such as paclitaxel (Taxol) and nocodazole, interfere with microtubule dynamics, thus precluding the normal function of the mitotic spindle and resulting in extensive mitotic arrest and cell death [26] . Upon treatment with spindle poisons, several kinases including CDK (cyclin-dependent kinase) 1 are activated [26] [27] [28] . CDK1 controls critical cell-cycle events by phosphorylating various substrates [29] .
In budding yeast, the protein phosphatase Cdc (cell division cycle) 14 controls mitotic exit by antagonizing Cdk function [30] . Mammals encode two Cdc14 orthologues, CDC14A and CDC14B [31] . The cellular function of CDC14A/B in higher eukaryotes has just begun to be elucidated [32] . CDC14A localizes at the centrosome in interphase and its deregulation disrupts centrosome separation and chromosome segregation [33] . Knockdown of CDC14B induces centriole amplification [34] , but it is dispensable for chromosome segregation and mitotic exit [35] . Interestingly, CDC14B has also been implicated in the DNAdamage response [36, 37] and DNA repair [38] .
We reported previously that KIBRA phosphorylation is regulated by the mitotic kinase Aurora and PP1 (protein phosphatase 1) [39] . KIBRA is hyperphosphorylated at Ser 539 in spindle poisoninduced mitosis [39] . In the present study, we have shown that, besides Ser 539 phosphorylation, phospho-regulation of KIBRA is also mediated by the mitotic kinase CDK1 and protein phosphatases CDC14A/B upon treatment with spindle poisons. Our results suggest further a potential role for KIBRA in mitosisrelated cell-cycle events, especially under microtubule stress.
EXPERIMENTAL

Expression constructs
The human KIBRA constructs have been described previously [20] . Myc-tagged human CDC14A and CDC14B expression constructs have been described previously [33] . Point mutations were generated by the QuikChange TM Site-Directed PCR mutagenesis kit (Stratagene) and verified by sequencing.
Cell culture and transfection
HEK (human embryonic kidney)-293T, HeLa and MCF-7 cell lines were maintained as described in [39] . All transient overexpression transfections were performed using Attractene (Qiagen) following the manufacturer's instructions. All siRNA (small interfering RNA) transfections were performed using HiPerFect (Qiagen). Nocodazole (100 ng/ml for 16-20 h) and Taxol (1 μM for 16 h) (Sigma) were used to arrest cells in mitosis. VX680 (Selleck Chemicals) was used at 1 μM as an Aurora kinase inhibitor. U0126 {a MEK [MAPK (mitogenactivated protein kinase)/ERK kinase]/ERK inhibitor}, SB203580 (p38 inhibitor) and SP600125 [JNK (c-Jun N-terminal kinase) inhibitor] were from LC Laboratories. RO-3306 (CDK1 inhibitor) and roscovitine (CDK inhibitor) were from ENZO Life Sciences. CDC14B siRNA (SMARTpool) was purchased from Dharmacon. All other chemicals were from either Sigma or Thermo Fisher.
Establishment of Tet-On-inducible cell lines
The parental MCF-7-rtTA cell line was purchased from Clontech Laboratories. The cell line expressing WT (wild-type) KIBRA has been described previously [39] . The MCF-Tet-On-inducible cell line expressing the KIBRA-4SA (KIBRA with four serine residues changed to alanine) mutant was established similarly. Cells were maintained in medium containing Tet system-approved fetal bovine serum (Clontech Laboratories).
Immunoprecipitation, Western blot analysis and metabolic labelling
Immunoprecipitation, Western blotting and metabolic labelling assays were carried out as described previously [39] . [ 32 P]P i was purchased from MP Biomedicals.
Antibodies
Rabbit polyclonal and mouse monoclonal antibodies against human KIBRA have been described previously [39] . Rabbit polyclonal phospho-specific antibodies against KIBRA Ser 542 , Ser 548 and Ser 931 were generated and purified by AbMart. The anti-(phospho-Ser 539 KIBRA) antibody has been described previously [39] . Anti-FLAG, anti-HA (haemagglutin) and anti-Myc antibodies were from Sigma. Anti-β-actin, anti-ERK, anti-cyclin B and anti-GFP (green fluorescent protein) antibodies were from Santa Cruz Biotechnology. Anti-Aurora-A, anti-GST (glutathione transferase) and anti-His 6 
λ-Phosphatase treatment
Cells were lysed in Nonidet P-40 buffer and treated with λ-phosphatase (New England Biolabs) as described in [39] .
Recombinant protein purification
The GST-tagged proteins were bacterially expressed and purified on GSTrap FF affinity columns (GE Healthcare) following the manufacturer's instructions. To make His 6 -tagged human CDC14A/B and their corresponding catalytically inactive phosphatases, full-length CDC14A/B and CDC14A-C278S/CDC14B-C314S cDNAs were subcloned into the pET21c vector (Novagen/EMD Chemicals). The proteins were expressed and purified on HisPur TM Cobalt spin columns (Thermo Scientific/Pierce) following the manufacturer's instructions. His 6 -YAP was expressed and purified similarly. The Aurora-A kinase has been described previously [39] .
In vitro kinase assay
GST-KIBRA (1-2 μg) was incubated with 10 units of recombinant CDK1-cyclin B complex (New England Biolabs) or 100 ng of CDK1-cyclin B (SignalChem) or HeLa cell total lysate (treated with DMSO or Taxol) in kinase buffer [39] in the presence of 5 μCi of [γ -32 P]ATP (3000 Ci/mmol) (PerkinElmer). MEK1, p38α, JNK1, JNK2 and CDK5 active kinases were purchased from SignalChem. The samples were resolved by SDS/PAGE (8 or 4-20 % gels), transferred on to PVDF membranes (Millipore) and visualized by autoradiography followed by Western blotting.
Flow cytometry
Alexa Fluor ® 488-annexin V/Dead cell apoptosis kit was from Invitrogen. Propidium iodide was purchased from Sigma. The cell-cycle profile was analysed using a standard protocol [40] .
In vitro dephosphorylation/phosphatase assay
GST-KIBRA-M or GST-KIBRA-C was phosphorylated by CDK1-cyclin B or Aurora-A in vitro as described in [39] . Phosphorylated GST-KIBRA was pulled down by glutathioneagarose (Santa Cruz Biotechnology) and the dephosphorylation assay was performed as described previously [39] . The reaction mixture was incubated at 30
• C for 45 min. The relative amounts of 32 P released into the supernatant, as well as the 32 P bound to GST-KIBRA, were quantified using a liquid-scintillation counter (Beckman LS6500).
Statistical analysis
Statistical significance was performed using a two-tailed unpaired Student's t test. 32 P for an additional 2 h as described in [39] . Immunoprecipitated products were separated by SDS/PAGE and transferred on to PVDF membranes, followed by autoradiography and Western blot analysis. (B) GST-KIBRA-M and -C proteins were used as substrates for in vitro kinase assays with asynchronized ( − ) or Taxol-treated ( + ) HeLa cell lysates in the presence of kinase inhibitors as indicated. The Aurora inhibitor VX680 was used at 1 μM and roscovitine was used at 10 μM for inhibiting CDK1. 32 P incorporation was revealed by autoradiography. The Western blot shows the substrate loading. The relative band intensity (normalized to the amount of protein) was quantified by Alphaview 1.3.0.7 software (Alpha Innotech). (C) GST-KIBRA-M and -C proteins were used as substrates for in vitro kinase assays with mock-or CDK1-depleted Taxol-treated cell lysates [27, 43] . GST-KIBRA was pulled down by glutathione-agarose and visualized by autoradiography and Western blot analysis. Total cell lysates were subjected to Western blot analysis with the indicated antibodies. The relative band intensity (normalized to the amount of protein) was quantified as in (B). (D) GST-KIBRA-N, -M and -C proteins were used as substrates for in vitro kinase assays with purified CDK1-cyclin B complex. Molecular masses (M) are indicated in kDa. IP, immunoprecipitation; WB, Western blot.
RESULTS AND DISCUSSION
KIBRA is phosphorylated by CDK1
We previously identified Ser 539 of KIBRA as a major phosphorylation site for Aurora kinases in mitosis [39] . To investigate further whether additional phosphorylation of KIBRA occurs during spindle-stress-induced mitosis, we performed metabolic labelling on a transfected KIBRA S539A mutant. As shown in Figure 1 . Roscovitine inhibits CDK1, CDK2 and CDK5 [41, 42] . CDK1 is a well-known mitotic kinase and is activated during spindle poison-arrested mitosis [27, 28, 39, 43] . CDK2 regulates G 1 -S-phase transition [44, 45] and is not activated by Taxol treatment [46] . CDK5 failed to phosphorylate KIBRA in vitro (Supplementary Figure S1 at http://www.BiochemJ.org/bj/447/bj4470093add.htm). Thus our results identify CDK1 as a likely candidate. Addition of both VX680 (an Aurora kinase inhibitor) and roscovitine inhibitors abolished the phosphorylation of KIBRA ( Figure 1B , lanes 5 and 10), suggesting that CDK1 and Aurora are the major kinases responsible for Taxol-induced KIBRA phosphorylation.
To confirm further that KIBRA phosphorylation is CDK1-dependent, we depleted CDK1 in Taxol-treated mitotic cell lysates [27, 43] and used them for in vitro kinase assays. shows that CDK1 depletion reduced phosphorylation of GST-KIBRA-M and -C by 50 % and 40 % respectively (top row, compare lanes 2 and 1, and lanes 4 and 3). Indeed, purified CDK1-cyclin B complex phosphorylated both GST-KIBRA-M and -C ( Figure 1D ). Taken together, these results indicate that CDK1 phosphorylates KIBRA directly in vitro.
MAPKs are not responsible for Taxol-induced phosphorylation of KIBRA
Since MAPKs, including MEK/ERK, JNK and p38, and CDK1 are all proline-directed kinases, we tested whether these kinases phosphorylate KIBRA. JNK1 or JNK2 could not phosphorylate KIBRA, whereas the same amounts of these kinases robustly phosphorylated their known substrate YAP [47] (Figure 2A ). Consistent with a previous study [48] , Taxol or nocodazole treatment strongly inhibited the ERK and p38 kinase activity in HeLa cells ( Figures 2B and  2D ). Thus we considered MEK/ERK and p38 unlikely to be the kinases responsible for KIBRA phosphorylation under spindle stress. Indeed, in vitro kinase assays demonstrated that KIBRA is not a suitable substrate for MEK1 ( Figure 2C ) or p38α ( Figure 2E ). In line with these observations, addition of U0126 (a MEK/ERK inhibitor), SP600125 (a JNK1/2 inhibitor) or SB203580 (a MAPK p38 inhibitor) to the Taxol-treated cell lysates failed to inhibit 32 P incorporation into GST-KIBRA-M and -C (Supplementary Figure S2 at http://www.BiochemJ.org/bj/447/bj4470093add.htm). These data suggest that Taxol-induced KIBRA phosphorylation is independent of MEK, JNK and p38 kinase.
CDK1-cyclin B complex phosphorylates multiple sites in KIBRA in vitro
CDK1 recognizes a minimal Ser/Thr-Pro consensus site [49] . Sequence analysis showed that KIBRA-M contains a highly conserved region encompassing multiple proline-directed serine residues including Ser 535 , Ser 542 , Ser 544 and Ser 548 (SP cluster) around the Aurora-site Ser 539 ( Figure 3A ). To test whether this SP cluster is phosphorylated by CDK1, we mutated all four serine residues to non-phosphorylatable alanine residues and performed in vitro kinase assays. As shown in Figure 3(B) , the CDK1-dependent phosphorylation of GST-KIBRA-M is largely abolished when all four serine residues are changed to alanine (KIBRA-M-4SA), suggesting that CDK1 potentially phosphorylates this well conserved SP cluster ( Figure 3B) Figure 4D ). Using an inhibitor for CDK1, we demonstrated that phosphorylation of KIBRA Ser 542 and Ser 931 was CDK1-dependent ( Figure 4D ). Taken together, these results support the notion that Ser 542 and Ser 931 of KIBRA are phosphorylated during spindle damage stress in a CDK1-dependent manner. We reported recently that KIBRA phosphorylation peaked and coincided with increased cyclin B levels in mitosis [39] , supporting further that CDK1-dependent phosphorylation of KIBRA occurs in cells.
CDC14 phosphatases dephosphorylate KIBRA in vitro
To analyse the kinetic changes in KIBRA phosphorylation, we collected mitotic cells by nocodazole treatment, released the cells into normal medium and then determined KIBRA's phospho-level using phospho-antibodies. Phosphorylation of KIBRA Ser 542 and Ser 931 is clearly reduced during mitotic exit ( Figure 5A ), suggesting the presence of a potential phosphatase responsible for the dephosphorylation. The Cdc14 phosphatase controls mitotic exit by antagonizing/dephosphorylating the CDK1-phosphorylated substrates in yeast [30] . Furthermore, human CDC14 phosphatases have also been implicated in dephosphorylating proline-directed phosphorylation [31, [51] [52] [53] [54] [55] [56] [57] . Accordingly, co-transfection of WT CDC14A or CDC14B, but not their catalytically inactive (CS) mutants (C278S or C314S respectively), with KIBRA greatly enhanced the mobility of KIBRA, suggesting that KIBRA is dephosphorylated when CDC14 is overexpressed ( Figure 5B) . Expression of another cell-cycle phosphatase, CDC25A, or its DN (dominant-negative) mutant had no effects on KIBRA's mobility ( Figure 5B, lanes 6  and 7) .
To test whether KIBRA is a direct substrate for CDC14 phosphatases, we purified CDC14A/B phosphatases ( Figure 5C ) and performed in vitro dephosphorylation assays using CDK1-phosphorylated GST-KIBRA-M or GST-KIBRA-C as substrates. Figures 5(D) and 5(E) show that CDK1-mediated phosphorylation of KIBRA was greatly reduced by purified WT CDC14A or CDC14B, and the catalytically inactive (CS mutant) phosphatases failed to dephosphorylate CDK1-phosphorylated KIBRA. Whereas PP1 efficiently dephosphorylated Auroramediated KIBRA phosphorylation [39] , it only moderately dephosphorylated CDK1-phosphorylated KIBRA ( Figures 5D  and 5E ). As controls, we also included Aurora-A-phosphorylated KIBRA as a substrate for dephosphorylation assays. Our data show that neither CDC14A nor CDC14B dephosphorylated Aurora-A-mediated phosphorylation on KIBRA ( Figure 5D , columns marked by CDC14A* and CDC14B*), confirming their specificity. 
CDC14 dephosphorylates KIBRA in cells
Next, we explored further whether KIBRA could be dephosphorylated by CDC14 in cells. Consistent with the mobility-shift assays in Figure 5 (B), co-transfection of WT CDC14A or CDC14B, but not the CS mutants, almost completely dephosphorylated KIBRA at Ser 931 , Ser 548 and Ser 542 ( Figure 6A ). As expected, the Aurora-mediated Ser 539 phosphorylation of KIBRA was not affected ( Figure 6A , second bottom row), which aligns perfectly with our in vitro dephosphorylation data ( Figure 5D ). Importantly, knockdown of CDC14B alone was sufficient to increase the phosphorylation levels of KIBRA Ser 542 and Ser 931 , but not Ser 539 ( Figure 6B ). Taken together, these results indicate that KIBRA is a physiological substrate for CDC14 phosphatase.
CDC14 phosphatases associate with KIBRA
The CDC14A/B activity towards KIBRA prompted us to explore whether KIBRA forms a complex with CDC14A or CDC14B. To do so, we performed immunoprecipitation with transfected plasmids and found that the CDC14A-CS mutant, but not WT CDC14A, associated with KIBRA, suggesting that the catalytically inactive CDC14A functions as a binding trap for KIBRA ( Figure 6C ). The CDC14B-CS mutant also showed much stronger binding affinity to KIBRA than WT CDC14B ( Figure 6D ). To test whether phosphorylation of KIBRA Ser 542 , Ser 544 , Ser 548 and Ser 931 is involved in KIBRA's interaction with CDC14, we used the KIBRA-4SA mutant and performed coimmunoprecipitation. The KIBRA-4SA mutant showed similar binding affinity with CDC14-CS when compared with WT KIBRA in transfected cells ( Figure 6E , compare lane 8 with lane 7). However, whereas WT KIBRA bound to CDC14B or CDC14B-CS efficiently, the interaction between KIBRA-4SA and CDC14B was significantly weakened (for WT CDC14B) or abolished (for CDC14B-CS), indicating that CDK1-mediated phosphorylation of KIBRA is required for association with CDC14B ( Figure 6F ). However, our results cannot exclude the possibility that mutating the CDK1 phosphorylation sites of KIBRA affects KIBRA's conformation, leading to disassociation from CDC14B.
Results supporting the well-established role of Cdc14 in controlling mitotic exit were largely obtained from studies in yeast. The cellular function of CDC14A/B is not well understood in higher eukaryotes, probably due to the fact that very few substrates have been identified so far for CDC14 phosphatases [32] . The present study has identified KIBRA as a novel substrate for CDC14 phosphatase, which may advance our understanding towards the functions of CDC14. It is important to investigate whether the Hippo pathway and/or KIBRA regulates CDC14 activity during mitotic exit. Furthermore, the detailed temporal and spatial dephosphorylation of KIBRA also remains to be explored; the phosphoantibodies we have generated provide important tools to dissect the regulation of KIBRA under both physiological and spindle stress conditions. Figure  S4A at http://www.BiochemJ.org/bj/447/bj4470093add.htm). As expected, KIBRA and KIBRA-4SA have similar abilities to stimulate Lats1/2 phosphorylation (results not shown).
KIBRA promotes YAP Ser 127 phosphorylation (through Lats1/2 kinases) [20] , so we also tested whether CDK1-mediated phosphorylation of KIBRA changes its ability to promote YAP phosphorylation. No significant change was detected towards YAP Ser 127 phosphorylation (with or without Taxol treatment), regardless of whether KIBRA or KIBRA-4SA had been transfected into the cells (Supplementary Figure S4B) . These results suggest that phosphorylation of KIBRA on Ser 542 , Ser 544 , Ser 548 and Ser 931 does not significantly affect Hippo-YAP activity.
Phospho-regulation of KIBRA by CDK1 and CDC14 affects cell-cycle progression CDK1 and CDC14 are well-established regulators of the cell cycle, and so we examined further the functional significance of KIBRA phosphorylation mediated by CDK1 and CDC14 in cell-cycle progression. To do so, we established an inducible KIBRA-expressing system ( Figure 7A ). Under normal culture conditions, expressing KIBRA or KIBRA-4SA had no discernible effect on the cell-cycle distribution ( Figure 7B ). Taxol KIBRA-4SA and KIBRA respectively) or G 1 -phase (23.24 % compared with 7.89 % for cells expressing KIBRA-4SA and KIBRA respectively) ( Figure 7C ). The fraction of cells in Sphase remained unaffected. These results suggest that elimination of KIBRA phosphorylation by CDK1 promoted cell exit from G 2 /M-phase into G 1 -phase. Thus phospho-regulation of KIBRA by CDK1 and CDC14 is required for proper cell-cycle progression under spindle damage stress. It will be interesting to explore how these cells could enter G 1 -phase in the presence of Taxol and what the fate of these cells may be.
We also counted the mitotic index and found indeed that cells expressing KIBRA-4SA could not arrest efficiently in mitosis, as revealed by a significant decrease in the number of cells stained by anti-(phospho-Ser 10 histone H3) antibody upon treatment with Taxol (Supplementary Table S1 at http://www.BiochemJ.org/bj/447/bj4470093add.htm). However, we found that all of these cell lines (Tet-control, Tet-KIBRA and Tet-KIBRA-4SA) responded to nocodazole (an agent that arrests cells in mitosis by depolymerizing microtubules) similarly with regard to cell-cycle distribution (Supplementary Table S2 at http://www.BiochemJ.org/bj/447/bj4470093add.htm) or mitotic index (Supplementary Table S3 at http://www.BiochemJ.org/ bj/447/bj4470093add.htm). Anti-mitotic agents, such as Taxol, have been widely used for treatment of several types of cancers, including ovarian and breast cancer [24, 25] . Although these drugs are known to induce apoptotic cell death, the biochemical mechanisms and signalling pathways underlying the toxicity are not clearly understood [59] . Interestingly, Lats2 knockdown sensitized cells to the spindle poison nocodazole [60] . Furthermore, the Hippo pathway effectors YAP and TAZ confer resistance to Taxol in ovarian and breast cancer cells respectively [61, 62] . Thus the Hippo signalling pathway may also function as a sensor linking the signal elicited by spindle poisons to apoptotic cell death. Future studies are needed to determine the role of KIBRA and its phosphorylation in anti-mitotic drug-induced apoptosis and the underlying mechanisms/signalling pathways. Such studies may have implications in cancer treatment with anti-mitotic drugs since Taxol-resistance is a major clinical challenge in Taxol-treated patients [26] .
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